Andere Sprachen BioAtla, Inc.

Aktien

A2QLBN

US09077B1044

BCAB

Markt geschlossen - Nasdaq Andere Börsenplätze 22:30:01 03.05.2024			% 5 Tage	% 1. Jan.
3,25 ^USD	+2,85 %		+27,95 %	+32,11 %

27.03.	BIOATLA, INC. : HC Wainwright behält seine Kaufempfehlung bei	ZM
26.03.	Transcript : BioAtla, Inc., Q4 2023 Earnings Call, Mar 26, 2024

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

BioAtla Announces Upcoming Poster Presentation at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting	24.04.
BioAtla Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Progress	26.03.
BioAtla, Inc. Reports Earnings Results for the Fourth Quarter and Full Year Ended December 31, 2023	26.03.
BioAtla to Announce Fourth Quarter and Full-Year 2023 Financial Results and Provide Business Highlights on March 26, 2024	19.03.
BioAtla Announces Poster Presentations at the 2024 American Association for Cancer Research (AACR) Annual Meeting	07.03.
Sector Update: Health Care Stocks Rise in Late Afternoon Trading	21.12.
Sector Update: Health Care Stocks Advance in Afternoon Trading	21.12.
BioAtla Rallies After CEO Buys 50,000 Shares	21.12.
BioAtla to Participate in the 42nd Annual J.P. Morgan Healthcare Conference	20.12.
BioAtla, Inc.(NasdaqGM:BCAB) dropped from NASDAQ Biotechnology Index	15.12.
BioAtla Hosting Virtual R&D Day to Highlight BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types	13.12.
Bioatla Hosting Virtual R&D Day to Highlight Ba3071 Cab-Ctla-4 Phase 1 Data in Multiple Solid Tumor Types	13.12.
BioAtla to Host Virtual R&D Day to Review BA3071 CAB-CTLA-4 Phase 1 Data in Multiple Solid Tumor Types on Wednesday, December 13, 2023	06.12.
Sector Update: Health Care Stocks Slipping Tuesday Afternoon	05.12.
BioAtla Says Clinical Benefits, Safety Profile Support Further Evaluation of Potential Lung Cancer Therapy	05.12.
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05.12.
BioAtla Presented Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05.12.
BioAtla, Inc. Presents Phase 2 Clinical Trial Data at the IASLC 2023 North America Conference on Lung Cancer and Virtual KOL Event	05.12.
BioAtla to Participate in the JMP Securities Hematology and Oncology Summit	30.11.
BioAtla to Host Virtual KOL Event to Review IASLC Data on BA3011 in NSCLC	28.11.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen BioAtla, Inc.

Aktien

A2QLBN

US09077B1044

BCAB

Andere Sprachen

Filter